A historic push to lower prescription drug costs under Medicaid has seen every U.S. state, Washington, D.C., and Puerto Rico express interest in joining a new federal pricing arrangement, with nearly half already securing agreements. The move marks a significant expansion of efforts to curb medication expenses for millions of low-income Americans enrolled in the program. Officials have framed the initiative as a potential political game-changer ahead of key elections, though implementation details and long-term impact remain under scrutiny. With bipartisan support and broad participation, the program could reshape how states negotiate drug prices—but challenges in execution may test its effectiveness.
All 50 states, Washington, D.C., and Puerto Rico have applied to participate in an arrangement intended to give lower drug prices to Medicaid programs, President Trump said Friday. “This one thing alone should win us the midterms,” Trump told reporters in the Oval Office. Forty states and Puerto Rico have already signed agreements, the Centers...
